Ketorolac
- Generic Name
- Ketorolac
- Brand Names
- Acular, Acuvail, Omidria, Readysharp Anesthetics Plus Ketorolac, Sprix, Toradol, Toronova Suik
- Drug Type
- Small Molecule
- Chemical Formula
- C15H13NO3
- CAS Number
- 74103-06-3
- Unique Ingredient Identifier
- YZI5105V0L
- Background
Ketorolac is a Non-steroidal anti-inflammatory drug (NSAID) and is commercially available as an oral tablet, injectable, nasal spray and as an ophthalmic solution.
...
- Indication
Ketorolac is a Non-steroidal anti-inflammatory drug (NSAID) and has antipyretic, analgesic and anti-inflammatory properties. It is indicated for short term management of acute pain that requires the calibre of pain management offered by opioids. Clinicians may choose to initiate ketorolac to manage post-operative pain, spinal and soft tissue pain, rheumatoid...
- Associated Conditions
- Acute Migraine, Eye Pain, Inflammation, Macular Edema, Cystoid, Ocular Itching, Pericarditis Acute, Pseudophakic Cystoid Macular Oedema, Severe Acute Pain, Acute, moderate Pain, Chronic aphakic cystoid macular edema, Intraoperative miosis, Postoperative ocular pain
- Associated Therapies
- -
Tolerability, Safety and Pharmacokinetics of Four Formulations of Ketorolac Tromethamine in Healthy Volunteers
- First Posted Date
- 2011-05-18
- Last Posted Date
- 2017-03-16
- Lead Sponsor
- Egalet Ltd
- Target Recruit Count
- 16
- Registration Number
- NCT01355588
- Locations
- 🇬🇧
Medeval Ltd, Manchester, United Kingdom
Study of the Safety, Tolerability and Analgesic Efficacy of Multiple Doses of Ketorolac Tromethamine (IN) for Postoperative Pain
- First Posted Date
- 2011-05-10
- Last Posted Date
- 2012-10-18
- Lead Sponsor
- American Regent, Inc.
- Target Recruit Count
- 127
- Registration Number
- NCT01351090
- Locations
- 🇳🇿
Waikato Clinical Research, Hamilton, New Zealand
Safety and Efficacy of Multiple Doses of Ketorolac Tromethamine Administered Intranasally for Postoperative Pain
- First Posted Date
- 2011-05-04
- Last Posted Date
- 2017-02-08
- Lead Sponsor
- Egalet Ltd
- Target Recruit Count
- 300
- Registration Number
- NCT01347853
- Locations
- 🇳🇿
Waikato Clinical Research, Hamilton, New Zealand
Use of Local Infiltration Analgesia Following Total Hip Arthroplasty
- Conditions
- Interventions
- First Posted Date
- 2011-04-29
- Last Posted Date
- 2013-01-23
- Lead Sponsor
- University of Aarhus
- Target Recruit Count
- 80
- Registration Number
- NCT01344395
- Locations
- 🇩🇰
Aarhus University Hospital, Aarhus, Denmark
Disposition of Intravenous Ketorolac
- First Posted Date
- 2011-02-08
- Last Posted Date
- 2011-12-13
- Lead Sponsor
- Universitaire Ziekenhuizen KU Leuven
- Target Recruit Count
- 42
- Registration Number
- NCT01291472
- Locations
- 🇧🇪
University Hospitals Leuven, Leuven, Belgium
Valproate Versus Ketorolac Versus Metoclopramide
- Conditions
- Interventions
- First Posted Date
- 2010-12-29
- Last Posted Date
- 2018-06-04
- Lead Sponsor
- Montefiore Medical Center
- Target Recruit Count
- 330
- Registration Number
- NCT01267864
- Locations
- 🇺🇸
Montefiore Medical Center, Bronx, New York, United States
Study of Whether 15 mg Dose of Ketorolac IV is as Effective as a 30 mg Dose.
- First Posted Date
- 2010-10-29
- Last Posted Date
- 2010-10-29
- Lead Sponsor
- University of Calgary
- Target Recruit Count
- 50
- Registration Number
- NCT01230463
- Locations
- 🇨🇦
Foothills Medical Centre, Calgary, Alberta, Canada
Ketorolac Effects on Post-operative Pain and Bone Healing
- First Posted Date
- 2010-05-31
- Last Posted Date
- 2019-08-21
- Lead Sponsor
- Beth Israel Deaconess Medical Center
- Target Recruit Count
- 18
- Registration Number
- NCT01133639
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Efficacy of Multimodal Perioperative Analgesia With Periarticular Drug Injection in Total Knee Arthroplasty(TKA)
- Conditions
- Interventions
- First Posted Date
- 2010-01-05
- Last Posted Date
- 2013-11-08
- Lead Sponsor
- Towson Orthopaedic Associates
- Target Recruit Count
- 160
- Registration Number
- NCT01042093
A Comparison of Prostaglandin E2 (PGE2) Inhibition of Acuvail(Ketorolac 0.45%), Xibrom (Bromfenac 0.09%)and Nevanac (Nepafenac)in Patients Undergoing Phacoemulsification
- Conditions
- Interventions
- First Posted Date
- 2009-11-30
- Last Posted Date
- 2011-08-31
- Lead Sponsor
- Frank A. Bucci, Jr., M.D.
- Target Recruit Count
- 126
- Registration Number
- NCT01021761
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.